Efficacy and Safety of Everolimus in Korean Patients with Metastatic Renal Cell Carcinoma Following Treatment Failure with a Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor
Kwonoh Park, Jae-Lyun Lee, Jin-Hee Ahn, Kyoo Hyung Lee, In-Gab Jeong, Cheryn Song, Bumsik Hong, Jun Hyuk Hong, Hanjong Ahn
Cancer Res Treat. 2014;46(4):339-347. Published online 2014 Jul 16 DOI: https://doi.org/10.4143/crt.2013.154
Citations to this article as recorded by 
Resistance to Systemic Agents in Renal Cell Carcinoma Predict and Overcome Genomic Strategies Adopted by Tumor
Veronica Mollica, Vincenzo Di Nunno, Lidia Gatto, Matteo Santoni, Marina Scarpelli, Alessia Cimadamore, Antonio Lopez-Beltran, Liang Cheng, Nicola Battelli, Rodolfo Montironi, Francesco Massari
Cancers.2019; 11(6): 830. CrossRef
Oral stomatitis and mTOR inhibitors: A review of current evidence in 20,915 patients
L Lo Muzio, C Arena, G Troiano, A Villa
Oral Diseases.2018; 24(1-2): 144. CrossRef